Peginterferon alfa-2a

聚乙二醇干扰素α-2a

Report date: 2026/05/13 20:02:10

Base Information

Drug NamePeginterferon alfa-2a
Drug Alias NamePeginterferon alpha-2a培干扰素 α-2aPegylated interferon-alpha-2aPeginterferon α-2aPEG interferon-α-2a +[15] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocythemia, Essential +[20] 
Global Approved IndicationsHepatitis C, ChronicHepatitis CHepatitis B, Chronic +[4] 
Approved Indications in ChinaHepatitis C, ChronicHepatitis B, Chronic
Original Approved Country/TerritoryEU
Original Approved Date2002/06/20
Country/TerritoryBelgiumBulgariaCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityGHN Pharma Nordic ABPharmaand GmbH +[11] 
Inactive CompaniesSciclone PharmaceuticalsRoche Pharma AgJohannes Gutenberg-University Mainz +[11] 
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersColonic Neoplasms +[7] 
Inactive IndicationsThrombocythemia, EssentialHemophilia AAnemia +[13] 

Other Information

ATC CodeL03AB11
Related LinksWikipediaDrugBankKEGG